Marimekko Corporation
25.9.2026 17:45:00 CEST | Globenewswire | Press release
Marimekko Corporation: Repurchase of own shares during week 39/2026
Marimekko Corporation: Repurchase of own shares during week 39/2026
Marimekko Corporation, Stock Exchange Release, 25 September 2026 at 6.45 p.m. EEST
Marimekko Corporation: Repurchase of own shares during week 39/2026
Marimekko Corporation has acquired its own shares during week 39 in the Helsinki Stock Exchange as follows:
| Trade date | Shares | Average price / share | Total cost |
| 21.9.2026 | 12,700 | 9.5713 | 121,555.51 |
| 22.9.2026 | 12,442 | 9.6475 | 120,034.20 |
| 23.9.2026 | 11,788 | 9.6018 | 113,186.02 |
| 24.9.2026 | 12,296 | 9.5415 | 117,322.28 |
| 25.9.2026 | 13,800 | 9.5130 | 131,279.40 |
| Total amount, week 39 | 63,026 | 9.5735 | 603,377.41 |
Marimekko Corporation now holds a total of 196,486 shares including the shares repurchased on 25 September 2026.
On 14 September 2026, Marimekko announced that it will start acquiring the company’s own shares based on the authorization granted by the Annual General Meeting held on 16 April 2026. The repurchase of own shares is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.
Details of the transactions are included as an appendix of this announcement.
On behalf of Marimekko Corporation
EVLI OYJ
Aleksi Jalava
Further information:
Anna Tuominen
tel. +358 40 584 6944
anna.tuominen@marimekko.com
DISTRIBUTION:
Nasdaq Helsinki Ltd
Key media
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom